Clinical Trial

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-14
Trial Details
NCT Number NCT07511205
Lead Sponsor AstraZeneca
Collaborators: Parexel
Conditions Healthy Participants, Obesity
Enrollment 104 participants
Start Date 2026-03-30
Primary Completion 2027-04-09 (estimated)
Study Completion 2027-11-17 (estimated)
Updated on ClinicalTrials.gov 2026-08-10